Publicacións en colaboración con investigadores/as de Cairo University (1)

2017

  1. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

    European Journal of Cancer, Vol. 82, pp. 237-246